Sickle beta-thalassemia, the third form

The third form of sickle cell disease, after homozygous SS and compound heterozygous SC, is sickle beta-thalassemia. A person with sickle beta-thalassemia carries one hemoglobin S allele on one beta-globin gene and a beta-thalassemia allele on the other. The clinical picture and severity depend on whether the thalassemia allele is the beta-zero variant, which produces no beta-globin, or the beta-plus variant, which produces a reduced amount of normal beta-globin.

Sickle beta-zero thalassemia (S/beta-0) clinically resembles homozygous SS in most respects, with frequent vaso-occlusive crises, acute chest syndrome, splenic and renal complications, and substantial disease burden. Sickle beta-plus thalassemia (S/beta-+) ranges from a mild phenotype to a moderate one depending on the specific beta-plus mutation and the residual normal beta-globin output. The clinical literature treats SS and S/beta-0 together for many recommendations because the phenotypes are so similar, and treats S/beta-+ as a separate, generally milder, group.

What sickle beta-thalassemia is

Beta-thalassemia is a group of inherited anemias caused by reduced or absent production of beta-globin from one or both beta-globin alleles. The molecular basis is a wide spectrum of HBB variants that disrupt transcription, splicing, translation, or stability of beta-globin mRNA. Hundreds of variants are recognized. The variants are grouped functionally into beta-zero (no beta-globin output) and beta-plus (reduced beta-globin output, with the residual proportion depending on the specific variant).

A person with one hemoglobin S allele and one beta-thalassemia allele has compound heterozygous disease. Hemoglobin electrophoresis shows hemoglobin S, no or reduced hemoglobin A (depending on whether the thalassemia allele is beta-zero or beta-plus), variable elevation of hemoglobin A2 and fetal hemoglobin, and occasionally hemoglobin C or other variants if a third allele is present in compound. The blood smear shows the morphological features of beta-thalassemia (microcytosis, target cells, basophilic stippling) along with sickled cells.

The clinical phenotype follows the proportion of hemoglobin S in red cells. In S/beta-0, with no normal beta-globin, the proportion of hemoglobin S is high and polymerization-driven vaso-occlusion is similar to that in SS. In S/beta-+, the residual normal beta-globin reduces the proportion of S and partially blunts the polymerization, producing a milder course in many cases.

Reported incidence in the United States runs in the low hundreds per year combined across both subforms. The condition is most common in populations with high prevalence of both sickle and beta-thalassemia alleles, including Mediterranean, Middle Eastern, South Asian, and Caribbean populations.

Detection

Newborn screening uses the same assays as for other hemoglobinopathies: isoelectric focusing, HPLC, or capillary electrophoresis on the dried blood spot. The screening pattern in S/beta-0 thalassemia at birth shows hemoglobin S and fetal hemoglobin without adult A, which is indistinguishable from homozygous SS at the newborn screen. Confirmation at 6 to 12 months differentiates the two: SS shows S and fetal hemoglobin transitioning to S alone, while S/beta-0 shows S and elevated A2. HBB sequencing characterizes the specific thalassemia variant.

S/beta-+ thalassemia at birth shows hemoglobin S, hemoglobin A (in reduced amount), and fetal hemoglobin. The pattern is distinguishable from S trait (which shows A more than S) by the relative proportions and confirmed by sequencing.

What management looks like

Standard of care for S/beta-0 thalassemia parallels SS management: penicillin prophylaxis in young children, pneumococcal and meningococcal vaccination, folic acid supplementation, hydroxyurea as disease-modifying therapy from infancy or early childhood depending on disease severity, transfusion for stroke prevention and other indications, and the same surveillance schedule as SS for cerebral, cardiac, pulmonary, and renal complications. Crizanlizumab and gene therapy (casgevy and lyfgenia, both approved 2023) are options for severe disease. The 2024 withdrawal of voxelotor applies to this population as it does to other sickle disease forms.

S/beta-+ thalassemia is managed with a less aggressive baseline approach because the disease is typically milder. Hydroxyurea is used when frequent crises or other indicators of high disease burden warrant it. The decision threshold for transfusion, gene therapy, and other intensive interventions is calibrated to the specific phenotype rather than a default protocol.

Iron overload from transfusion or, less commonly, from increased gastrointestinal absorption, is managed with chelation therapy when regular transfusions or documented iron loading are present.

What this looks like for a family

A baby is born and the heel-prick is sent. The newborn screening report identifies a sickle pattern with no adult hemoglobin. At 9 months, repeat hemoglobin analysis shows S, fetal hemoglobin, and elevated A2 consistent with S/beta-0 thalassemia. HBB sequencing returns the specific beta-thalassemia variant. The family meets the pediatric hematologist. Penicillin prophylaxis begins. Hydroxyurea begins in the first year of life per current sickle cell management guidelines. Stroke surveillance with transcranial Doppler begins at age 2.

The clinical course over the next two decades looks like the SS course. The interventions, the crises, the surveillance, the difficult choices about gene therapy and chronic transfusion, all follow the SS template. The genetic distinction matters for counseling and family planning. The day-to-day medical management does not.

That is what S/beta-0 thalassemia care looks like in practice. The same clinical infrastructure that has been built around homozygous SS handles this condition, with a thalassemia annotation in the chart that occasionally matters for a specific decision and otherwise stays in the background.